AureoGen News

January 30, 2007 - AureoGen Biosciences enter into a license agreement with Takara Bio Inc., a $140 million biotech company located in Otsu, Japan. The agreement will provide AureoGen access to several patent protected antibiotic compounds, as well as a proprietary organism that produces the potent antifungal compound Aureobasidin A (AbA). AbA is the primary (genetic engineering) target for AureoGen’s efforts to prepare a novel broad spectrum antifungal drug.

October 15, 2006 - AureoGen Biosciences moves into a new 4,000 sq.ft. facility at 6475 Technology Avenue in Kalamazoo, MI. The new facility includes 3,000 sq.ft. of newly constructed state-of-the art lab space for the company research.

May 15, 2006 - AureoGen Biosciences receives a Small Business Innovation Research (SBIR) grant from the National Institutes of Allergy and Infectious Diseases. The successful completion of the AureoGen’s Phase I project “Novel Antifungals by Engineering a NRPS gene” (see above) allowed the company to apply for, and be awarded, Phase II funding for this project. The Phase II SBIR grant amounts to $1,925,001, over a period of three years.

April 1, 2005 - AureoGen Biosciences receives a $225,000 investment from the Bioscience Research and Commercialization Center (BRCC) at the Western Michigan University in Kalamazoo MI.

September 28th, 2004 - AureoGen Biosciences, Inc., receives award from the National Institutes of Standards and Technology Advanced Technology Program (NIST/ATP) -- AureoGen Biosciences Inc., was selected from among 870 applicants to receive one of the 32 NIST/ATP awards granted for 2004. [With a funding rate of only 3.68%, 2004 is the most competitive year since inception of the NIST/ATP program in 1990.] AureoGen’s three year grant totals $1,450,508.00 and will be used to fund a project entitled “A Genetic Engineering Technology Platform for Production of Novel Cyclic Peptide-Based Drugs”. The total cost of the project is $2,242,542.00, with the remaining funds being contributed as a match from AureoGen.

September 17th, 2004 - AureoGen Biosciences, Inc., receives Small Business Innovation Research (SBIR)award from the National Institutes of Allergy and Infectious Diseases -- AureoGen Biosciences Inc., was awarded Phase I funding for a project entitled Novel Antifungals by Engineering a NRPS gene. The Phase I SBIR grant amounts to $162,982.00 and is to fund the initial (6 months) of the project. Successful completion of the Phase I research will allow AureoGen to apply for continued, Phase II funding for completion of the later stages of the project. The Phase I grant is scheduled to start October 1, 2004 and be completed by March 31, 2005.

June 29th, 2004 - AureoGen Biosciences Inc., is a Michigan Tri-Technology Corridor (MTTC) 2004 Award Winners -- AureoGen Biosciences Inc., was awarded a three year, $1,994,476, convertible loan from the MTTC. The MTTC loan is part of the Michigan Economic Development Corporation efforts to promote the development of new businesses in the State of Michigan. AureoGen’s award will be used for the development of genetic tools and methodologies that will allow for efficient genetic engineering of cyclic peptide producing organisms. Cyclic peptides constitute an important family of natural product drugs and the engineering technology to be developed (by AureoGen) will allow generation of novel antifungal, antibacterial, and anticancer drugs. The start date for the award is October 31, 2004, and the award is for three years with annual milestones to be completed for continued funding. As part of the award, AureoGen has granted Western Michigan University a total of $371,607.00 to fund research in the laboratory of Dr. John R. Geiser, at Department of Biological Sciences. Dr. Geiser’s laboratory is expected to help AureoGen find new ways to engineer the biosynthesis complexes responsible for production of cyclic peptides. As part of AureoGen’s funding for the MEDC, Dr. Geiser’s grant is for the same three year period and is contingent upon achieving annual milestones. Dr Geiser’s grant has a start date of October 1, 2004.

September 4th, 2003- AureoGen Biosciences, Inc., is awarded $200,000 in start up funding from the Michigan Economic Development Corporation.